- Home
- IRON
IRON
Disc Medicine Inc.
as of 03-23-2026 3:52pm EST
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 2.3B | IPO Year: | 2020 |
| Target Price: | $103.18 | AVG Volume (30 days): | 520.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.01 | EPS Growth: | -51.77 |
| 52 Week Low/High: | $30.82 - $99.50 | Next Earning Date: | 05-06-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 283.52% |
| P/E Ratio: | -9.70 | Index: | N/A |
| Free Cash Flow: | -181326000.0 | FCF Growth: | N/A |
AI-Powered IRON Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Disc Medicine Inc. (IRON)
Chief Medical Officer
Avg Cost/Share
$65.97
Shares
7,378
Total Value
$486,069.02
Owned After
85,211
Chief Financial Officer
Avg Cost/Share
$69.06
Shares
353
Total Value
$24,377.09
Owned After
70,990
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$62.86
Shares
13,264
Total Value
$833,775.04
Owned After
226,064
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$62.86
Shares
5,531
Total Value
$347,678.66
Owned After
80,998
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$62.86
Shares
2,853
Total Value
$179,339.58
Owned After
52,173
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$62.86
Shares
3,256
Total Value
$204,672.16
Owned After
85,211
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$62.86
Shares
3,231
Total Value
$203,100.66
Owned After
54,324
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$69.74
Shares
1,000
Total Value
$69,740.00
Owned After
52,173
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$78.52
Shares
6,500
Total Value
$511,471.76
Owned After
52,173
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Savage William Jacob | IRON | Chief Medical Officer | Mar 2, 2026 | Sell | $65.97 | 7,378 | $486,069.02 | 85,211 | |
| Franchi Jean M. | IRON | Chief Financial Officer | Feb 25, 2026 | Sell | $69.06 | 353 | $24,377.09 | 70,990 | |
| Quisel John D | IRON | Chief Executive Officer | Feb 17, 2026 | Sell | $62.86 | 13,264 | $833,775.04 | 226,064 | |
| Stephenson Pamela | IRON | Chief Commercial Officer | Feb 17, 2026 | Sell | $62.86 | 5,531 | $347,678.66 | 80,998 | |
| Khara Rahul | IRON | Chief Legal Officer | Feb 17, 2026 | Sell | $62.86 | 2,853 | $179,339.58 | 52,173 | |
| Savage William Jacob | IRON | Chief Medical Officer | Feb 17, 2026 | Sell | $62.86 | 3,256 | $204,672.16 | 85,211 | |
| Yu Jonathan Yen-Wen | IRON | Chief Operating Officer | Feb 17, 2026 | Sell | $62.86 | 3,231 | $203,100.66 | 54,324 | |
| Khara Rahul | IRON | Chief Legal Officer | Jan 20, 2026 | Sell | $69.74 | 1,000 | $69,740.00 | 52,173 | |
| Khara Rahul | IRON | Chief Legal Officer | Jan 2, 2026 | Sell | $78.52 | 6,500 | $511,471.76 | 52,173 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 26, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLFeb 26, 2026 · 100% conf.
1D
-0.09%
$67.85
Act: -1.96%
5D
-2.90%
$65.94
Act: -11.15%
20D
+20.21%
$81.63
8-K
0001816736false00018167362026-02-262026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2026
DISC MEDICINE, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-39438
85-1612845
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
321 Arsenal Street Suite 101
Watertown, Massachusetts
02472
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 617 674-9274
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
IRON
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 26, 2026, Disc Medicine, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025 and provided a corporate update. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press release issued by Disc Medicine, Inc. on February 26, 2026, furnished herewith.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DISC MEDICINE, INC.
Date:
February 26, 2026
By:
/s/ John Quisel, J.D., Ph.D.
Name: John Quisel, J.D., Ph.D. Title: Chief Executive Officer
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
1D
-0.09%
$67.85
Act: -1.96%
5D
-2.90%
$65.94
Act: -11.15%
20D
+20.21%
$81.63
8-K
false000181673600018167362026-01-122026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 12, 2026
DISC MEDICINE, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-39438
85-1612845
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
321 Arsenal Street Suite 101
Watertown, Massachusetts
02472
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 617 674-9274
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
IRON
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On January 12, 2026, Disc Medicine, Inc. (the “Company”) issued a press release announcing, among other things, that its preliminary unaudited cash, cash equivalents and marketable securities as of December 31, 2025 were approximately $791 million. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The Company has not yet completed its year-end financial close process for the year ended December 31, 2025. This estimate of the Company’s cash, cash equivalents and marketable securities as of December 31, 2025 is preliminary and is subject to change upon completion of the Company’s financial statement closing procedures. The Company’s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to this preliminary result and, accordingly, does not express an opinion or any other form of assurance about it. Additional information and disclosure would be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2025. The information presented herein should not be considered a substitute for the financial information the Company files with the Securities and Exchange Commission in its annual report on Form 10-K for the year ended December 31, 2025. The Company has no intention or obligation to update the preliminary estimate of its cash, cash equivalents and marketable securities set forth above.
The information contained in Item 2.02 of this Current Report on Form 8-K is intended to be furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly provided by specific reference in such filing. Item 7.01 Regulation FD Disclosure. On January 12, 2026, the Company also announced its recent achievements and key business objectives and milestones for 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Commencing on January 12, 2026, the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference (the “Conference”). A copy of the Company's presentation materials that it intends to use at the Conference, including at a previously announced investor presentation on January 14, 2026, is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibits 99.1 and 99.2 attached hereto) is intended to be furnished and shall not be deemed “filed” for purpos
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
Q3 2025 Earnings
8-KNov 6, 2025
8-K
0001816736false00018167362025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 06, 2025
DISC MEDICINE, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-39438
85-1612845
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
321 Arsenal Street Suite 101
Watertown, Massachusetts
02472
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 617 674-9274
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
IRON
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, Disc Medicine, Inc. announced its financial results for the third quarter ended September 30, 2025 and provided a corporate update. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 2.02 of this Current Report on Form 8-K shall be deemed to be furnished and not filed:
Exhibit No.
Description
99.1
Press release issued by Disc Medicine, Inc. on November 6, 2025, furnished herewith.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DISC MEDICINE, INC.
Date:
November 6, 2025
By:
/s/ John Quisel, J.D., Ph.D.
Name: John Quisel, J.D., Ph.D. Title: Chief Executive Officer
Compare IRON vs Leading Stocks
See how IRON stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IRON Disc Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.